MITRAb Stock Overview
Develops, manufactures, and markets complex therapeutics in the areas of contraception, menopause, and hormone-dependent cancers in Belgium, Europe and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
Mithra Pharmaceuticals SA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €2.96 |
| 52 Week High | €6.05 |
| 52 Week Low | €1.65 |
| Beta | 0.73 |
| 11 Month Change | 0% |
| 3 Month Change | 15.66% |
| 1 Year Change | n/a |
| 33 Year Change | -82.98% |
| 5 Year Change | -87.37% |
| Change since IPO | -75.04% |
Recent News & Updates
Recent updates
Shareholder Returns
| MITRAb | GB Pharmaceuticals | GB Market | |
|---|---|---|---|
| 7D | 0% | -4.2% | -1.5% |
| 1Y | n/a | 12.7% | 5.8% |
Return vs Industry: Insufficient data to determine how MITRAb performed against the UK Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how MITRAb performed against the UK Market.
Price Volatility
| MITRAb volatility | |
|---|---|
| MITRAb Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 7.7% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in GB Market | 10.8% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: MITRAb has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine MITRAb's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 270 | David Solomon | www.mithra.com |
Mithra Pharmaceuticals SA develops, manufactures, and markets complex therapeutics in the areas of contraception, menopause, and hormone-dependent cancers in Belgium, Europe and internationally. Its development candidates include Estelle, a combined oral contraceptive that has completed phase III clinical trial; Donesta, which is in phase III clinical trial for estetrol-based oral hormone treatment; and products for neuroprotection and wound healing. The company also develops Myring, a contraceptive vaginal ring releasing a combination of hormones; Tibelia, a tablet composed of tibolone and a synthetic steroid used for hormone therapy in menopause; and Zoreline, a biodegradable subcutaneous implant for use in prostate and breast cancers, and benign gynecological indications.
Mithra Pharmaceuticals SA Fundamentals Summary
| MITRAb fundamental statistics | |
|---|---|
| Market cap | €100.90m |
| Earnings (TTM) | -€78.84m |
| Revenue (TTM) | €62.68m |
1.6x
P/S Ratio-1.3x
P/E RatioIs MITRAb overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MITRAb income statement (TTM) | |
|---|---|
| Revenue | €62.68m |
| Cost of Revenue | €20.97m |
| Gross Profit | €41.71m |
| Other Expenses | €120.55m |
| Earnings | -€78.84m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.14 |
| Gross Margin | 66.54% |
| Net Profit Margin | -125.79% |
| Debt/Equity Ratio | -3,048.5% |
How did MITRAb perform over the long term?
See historical performance and comparison